- Archives
- Elisa Alvarez-Garrido
The Impact of Venture Capital on Innovation: Beyond Portfolio Companies
This paper provides empirical evidence that not all VCs contribute equally to startup innovation, making the specialist versus generalist distinction the central analytical variable. Using a sample of 923 VC-backed biotech startups across 26 countries from 1996 to 2006, the paper finds that specialist VC firms (those concentrating their portfolio in a specific industry) are associated with a 40% faster speed to first patent compared to generalist VC firms, and up to 90% faster in moderate research environments. Two mechanisms drive this: specialist VCs help startups solve the value translation problem (converting scientific discovery into commercially viable innovation) and the regulatory problem (structuring the R&D process from inception so that all tests comply with drug development requirements). Critically, the paper separates selection effects from treatment effects, showing that specialist VCs are not merely picking better startups but are actively improving innovation outcomes.
Why is relevant?
This paper is directly relevant to founders in biotech, deeptech, and any science-based startup deciding which type of investor to pursue. The finding that specialist VC firms meaningfully accelerate patenting speed has a direct practical implication: when choosing between a generalist and a specialist investor at equal terms, the specialist's domain knowledge may be worth more than the brand or network of a generalist, particularly in technical fields where regulatory and value translation challenges are the primary bottlenecks to commercialization. The country research environment finding is equally useful for ecosystem thinkers: the paper shows that VC specialization matters most in moderate research environments and matters less where public research infrastructure is either very strong (which substitutes for investor expertise) or very weak (which makes VC expertise insufficient on its own). For VCs evaluating their own portfolio construction strategy, the paper provides a rare empirical quantification of the return on specialization in terms of portfolio company performance rather than fund-level financial returns.

Author
Elisa Alvarez-Garrido
Publication date
January 15th, 2020
Difficulty
Advanced
Keywords
- Venture capital
- startup innovation
- specialist VC
- generalist VC
- biotech
- patenting
- country research environment
- VC specialization
- treatment vs selection
Last update